Page 14 - Bharat Biotech
Shortage of transparency
Govt, companies must end opacity on vaccine supplies
 "Shortage of transparency")
Bharat Biotech gives request to Brazilian regulator for Covaxin approval
Earlier, Anvisa denied permission to import Covaxin after its authorities found that the plant in which the jab is being made did not meet the Good Manufacturing Practice (GMP) requirements
 "Bharat Biotech gives request to Brazilian regulator for Covaxin approval")
ICMR to examine effectiveness of SII's Covishield, Bharat Biotech's Covaxin
The Indian Council of Medical Research (ICMR) will conduct a survey from next week to examine the effectiveness of these vaccines in preventing progression of COVID into a severe form.
India a dysfunctional anarchy?
It is the people who lost as the government scored self-goals
 "India a dysfunctional anarchy?")
Bharat Biotech expects EUL from WHO for Covaxin by Jul-Sept period
Emergency Use Listing (EUL) is a procedure to streamline the process by which new or unlicensed products can be used during public health emergencies, according to WHO guidelines
 "Bharat Biotech expects EUL from WHO for Covaxin by Jul-Sept period")
WHO nod for Covaxin expected in July-September period: Bharat Biotech
Company says regulatory approvals for Covaxin are also in process in more than 60 countries, including the US, Brazil, Hungary
 "WHO nod for Covaxin expected in July-September period: Bharat Biotech")
Delhi yet to receive more Covid-19 vaccines for 18-44 group, says Atishi
Delhi is yet to receive more vaccines for the 18-44 age group and only private hospitals are giving jabs to beneficiaries in this category for now, Aam Aadmi Party MLA Atishi said on Tuesday
 "Delhi yet to receive more Covid-19 vaccines for 18-44 group, says Atishi")
Bharat Biotech's US partner Ocugen submits 'Master File' to FDA on Covaxin
Ocugen, Bharat Biotech's American partner for Covaxin, has submitted a 'Master File' to the US Food and Drug Administration prior to seeking an emergency use authorisation in that country
WHO seeks more details from Bharat Bio for emergency use listing of Covaxin
The World Health Organisation (WHO) said more information is required from Bharat Biotech, which is seeking emergency use listing (EUL) for its Covaxin vaccine for COVID-19. The latest Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process' guidance document dated May 18 on the WHO website said Bharat Biotech submitted EOI (Expression of Interest) on April 19 and that More information required. A pre-submission meeting is expected to be planned May-June 2021, the guidance document said. According to the WHO, submissions to it for prequalification or listing under the emergency use procedure are confidential. If a product submitted for assessment is found to meet the criteria for listing, WHO will publish the results widely. Duration of the emergency use listing process depends on the quality of the data submitted by the vaccine manufacturer and on those data meeting WHO criteria, according to the agency. Meanwhile, Bharat Biotech International Limited (BBIL) has conveyed
WHO seeks more info from Bharat Biotech for emergency listing of Covaxin
The documents showed Bharat Biotech submitted Expression of Interest with the WHO for emergency use listing (EUL) on April 19
Bharat Biotech may begin Covaxin trial for 2-18 age group in June
Bharat Biotech may begin paediatric trials of its Covid-19 vaccine Covaxin from June, said the company's Business Development and International Advocacy Head Dr Raches Ella on Sunday.
No consensus yet on Covid vaccine passport issue at WHO level: Govt
'As of now, as per WHO guidelines and guidelines by other countries, people with negative COVID test report are being allowed,' says Health Ministry Joint Secretary
Bharat Biotech may receive Covaxin drug substance from IIL in June
The Union health ministry said recently that it expects 750 million doses of Covishield to be available between August and December.
 "Bharat Biotech may receive Covaxin drug substance from IIL in June")
India is world's vaccine factory: What happens when it can't deliver
India stopped exporting Covid-19 vaccines in mid-April, leaving low-income and lower-middle-income countries in the lurch.
 "India is world's vaccine factory: What happens when it can't deliver")
Bharat Biotech adds 200 million dose per annum Covaxin capacity
The company said the quick ramp up of additional manufacturing capacities for Covaxin was done at Chiron Behring Vaccines, Ankleshwar Gujarat, a wholly owned subsidiary of Bharat Biotech
Bharat Biotech to ramp up Covaxin production, make 200 mn doses a year
'Product availability of additional doses to commence from Q4, 2021 at Chiron Behring Vaccines Ltd, located in Ankleshwar, Gujarat,' Bharat Biotech says
SII, Bharat Biotech to get bulk of Rs 15K-crore profit pool: Report
At present, SII sells its vaccine Covishield to the Centre for Rs 150 per dose, to state governments for Rs 300 and to private hospitals for Rs 600.
 "SII, Bharat Biotech to get bulk of Rs 15K-crore profit pool: Report")
No diversion, Bharat Biotech Pune plant as per Bombay HC order: Ajit Pawar
Maharashtra Deputy Chief Minister Ajit Pawar on Monday dismissed the allegation that he has diverted a Bharat Biotech project of manufacturing Covid-19 vaccines to his home district Pune
'Karnataka facility can produce 40-50 mn Covaxin doses a month by Aug-end'
Bharat Biotech's Covaxin manufacturing facility that is under construction in Karnataka would have a manufacturing capacity of 40 to 50 million doses a month by August-end, says state Health Minister
 "'Karnataka facility can produce 40-50 mn Covaxin doses a month by Aug-end'")
The way forward for firms
Indian firms need to prepare for export boom by vaccinating employees, their family members; and prioritise export market
 "The way forward for firms")